Roche AG, of Basel, Switzerland, said its Genentech unit reported that the global, randomized phase III ALEX study met its primary endpoint and showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival) compared to the tyrosine kinase receptor inhibitor crizotinib (Xalkori, Pfizer Inc.) in people with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.